Neuromagen Pharma Ltd., an Israel-based company developing a new class of drugs for the treatment of degenerative and senescence-associated diseases, announced on Thursday that it has named Prof Gal Ifergane, head of the Neurology Department at Soroka Medical Center as its first member to the Advisory Board.
Ifergane is serving as the head of Soroka's Medical Center Neurology department. He has served as a deputy director of the Medical Center. He created the vision for and headed the development of the Brain Medicine Division, which he also presently chairs.
Gil Ben-Menachem, Neuromagen's CEO, said, 'Prof. Ifergane brings to Neuromagen extensive expertise within the neurology field. His research and clinical experience will be of outmost importance as we move forward towards the clinic. We are honoured to have Prof. Ifergane on board, and are extremely happy to have a Be'er Sheva-based key opinion leader such as him joining our ranks.'
Zydus enters exclusive talks to acquire majority stake in Amplitude Surgical
Adcendo's ADCE-T02 Phase I study IND application receives US FDA approval
WHO grants Actinogen Medical's Xanamem/UE2343 non-proprietary name 'emestedastat'
IVFMD physicians named 2025 Castle Connolly Top Doctors
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Partillion Bioscience opens pre-orders for Nanovial Multicell Assay Antibody Discovery Kits
Champions Oncology expands bioanalytical services with new technology
Petauri's Nicole Lodowski named to MM+M's 40 Under 40 for 2025
WuXi XDC Cayman wins 'Best CDMO' at World ADC Awards 2024
Nektar Therapeutics agrees sale of Huntsville manufacturing facility and reagent supply business